Medtronic, Inc.

Medronic, Inc.

Medtronic, Inc. (cvg)

Walter H Olson

Vinod Sharma

William Frederick Kaemmerer

Xusheng Zhang

Wade M Demmer

Saul E Greenhut

Troy Edward Jackson

Robert J Nehls

James D Reinke

Jeffrey M Gillberg

Bruce D Gunderson

Mark L Brown

Vasant Padmanabhan

Xiaohong Zhou

David K Peterson

Gust H Bardy

Robert W Stadler

Rahul Mehra

Orhan Soykan

Kevin T Ousdigian

Paul J DeGroot

Robert T Taepke

Jennifer P Miller

ShaileshKumar V Musley

Timothy H Robinson

Amy C Dearking

Xiaoyi Min

Can Cinbis

Li Ping Wang

Gary F Prokop

Thomas J Mullen

Paul Gordon Krause

Raja N Ghanem

Luc Roland Mongeon

Michael R Hill

Joey Nakayama

Sourav Bhunia

Karen A Stone

King Y Moy

Cameron J Kaszas

Kenneth P Huberty

John R Lisowski

Steven J Mader

Gary J Stilwell

William J George

Vinrod Sharma

Techniques and systems for monitoring cardiac arrhythmias and delivering electrical stimulation therapy using a subcutaneous implantable cardioverter defibrillator (SICD) and a leadless pacing device (LPD) are described. For example, the SICD may detect a tachyarrhythmia within a first electrical signal from a heart and determine, based on the tachyarrhythmia, to deliver anti-tachyarrhythmia shock therapy to the patient to treat the detected arrhythmia. The LPD may receive communication from the SICD requesting the LPD deliver anti-tachycardia pacing to the heart and determine, based on a second electrical signal from the heart sensed by the LPD, whether to deliver anti-tachycardia pacing (ATP) to the heart. In this manner, the SICD and LPD may communicate to coordinate ATP and/or cardioversion/defibrillation therapy. In another example, the LPD may be configured to deliver post-shock pacing after detecting delivery of anti-tachyarrhythmia shock therapy.

Systems and methods for leadless pacing and shock therapy

A technique for identifying lead-related conditions, such as insulation breaches and/or externalization of lead conductors, includes analyzing characteristics of electrical signals generated on one or more electrode sensing vectors of the lead by a test signal to determine whether a lead-related condition exists. The characteristics of the electrical signals induced on the lead by the test signal may be significantly different on a lead having an insulation breach or externalized conductor than on a lead not having such lead-related conditions. As such, the implantable medical device may be subject to a known test signal and analyze the signals on the lead to detect lead-related conditions.

Identifying lead insulation breaches and externalization of lead conductors

An implantable medical device system detects and treats monomorphic ventricular tachycardia (VT). The system includes a sensing module for receiving a cardiac signal and a therapy delivery module including a capacitor and an output circuit. A control module is coupled to the sensing module and the therapy delivery module and is configured to detect a tachycardia from the cardiac signal and initiate charging of the capacitor in response to detecting the tachycardia. The control module performs a method for simultaneously monitoring a voltage on the capacitor and a morphology of the cardiac signal during the charging and controls the therapy delivery circuit to deliver a shock pulse at less than a programmed shock energy in response to both the voltage reaching at least a minimum voltage and the morphology being monomorphic.

Shock therapy for monomorphic detected ventricular tachycardia

Disclosed are compositions, methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of cells of targeted regions of the cardiac conduction system. In particular, a bio-pacemaker composition is delivered to cardiac cells to increase the intrinsic pacemaking rate of the cells, wherein the bio-pacemaker composition increases expression of a channel or subunit thereof that produces funny current and a T-type Cachannel or subunit thereof, and expresses one or more molecules that suppresses the expression of the wild type potassium channel.

Genetic modification of targeted regions of the cardiac conduction system

Disclosed are methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of the conduction system of the heart. In one embodiment, the invention provides a method of genetically modifying the cells by delivering to the cells one or more coding sequence in a genetic construct capable of modifying the expression of ion channels of the cells.

A medical device identifies a hemodynamically unstable arrhythmia based upon optical hemodynamic sensor signals. The optical hemodynamic sensor includes a light source for transmitting light corresponding to first and second wavelengths through a blood perfused tissue of a patient and a light detector for generating optical signals corresponding to an intensity of the detected light at the first and second wavelengths. At a low motion period for the patient, optical signals are obtained from the optical hemodynamic sensor and are analyzed to determine a baseline motion level for the patient. Subsequent signals obtained from the optical hemodynamic sensor are compared to the baseline motion levels, with only those signals corresponding to periods where motion does not exceed the baseline level of motion being further analyzed to determine if they are consistent with a hemodynamically unstable arrhythmia.

Method and apparatus for using an optical hemodynamic sensor to identify an unstable arrhythmia

SubQ ICDs are disclosed that are entirely implantable subcutaneously with minimal surgical intrusion into the body of the patient and provide distributed cardioversion-defibrillation sense and stimulation electrodes for delivery of cardioversion-defibrillation shock and pacing therapies across the heart when necessary. Configurations include one hermetically sealed housing with 1 or, optionally, 2 subcutaneous sensing and cardioversion-defibrillation therapy delivery leads or alternatively, 2 hermetically sealed housings interconnected by a power/signal cable. The housings are generally dynamically configurable to adjust to varying rib structure and associated articulation of the thoracic cavity and muscles. Further the housings may optionally be flexibly adjusted for ease of implant and patient comfort.

Subcutaneous cardioverter-defibrillator

In general, the invention is directed to systems and techniques for assessing a risk of ventricular tachyarrhythmia in a patient by measuring one or more biochemical markers that reflect the health of a patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more biomarkers. Based upon the results of the tests, the patient's risk of ventricular tachyarrhythmia may be assessed. When the patient is found to be at risk, the patient may receive an implantable medical device or drug therapy to address the risk.

Methods for identifying patients at risk for life threatening arrhythmias

Growing community of inventors

North Oaks, MN, United States of America

Walter H Olson